Status:

COMPLETED

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

Lead Sponsor:

Hoag Memorial Hospital Presbyterian

Conditions:

Brain and Central Nervous System Tumors

Eligibility:

All Genders

16+ years

Phase:

PHASE2

Brief Summary

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood...

Detailed Description

OBJECTIVES: * Determine the feasibility, side effects, and toxicity associated with intracranial cellular adoptive immunotherapy comprising aldesleukin-stimulated lymphokine-activated killer cells in...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of primary malignant glioblastoma multiforme (i.e., grade IV anaplastic astrocytoma)
  • Primary treatment (surgery, radiation, and/or chemotherapy) has been completed
  • Candidate for surgery and willing to undergo craniotomy
  • No progressive or recurrent disease
  • No residual disease that requires reoperation, additional gamma therapy, or other modality
  • PATIENT CHARACTERISTICS:
  • ECOG performance status (PS) 0-2 OR Karnofsky PS 70-100% (i.e., if symptomatic, bedridden \< half of a waking day)
  • Life expectancy ≥ 2 months
  • Not pregnant
  • Negative pregnancy test
  • U.S. residents only
  • No hematopoietic, hepatic, renal, cardiovascular, or pulmonary laboratory values or other medical circumstances that would preclude surgery or aldesleukin therapy
  • No serious concurrent medical or psychiatric illness that would preclude informed consent or study treatment
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • At least 4 weeks since prior anticancer therapy and recovered
  • Prior stereotactic or gamma knife radiosurgery allowed

Exclusion

    Key Trial Info

    Start Date :

    February 1 1999

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2012

    Estimated Enrollment :

    83 Patients enrolled

    Trial Details

    Trial ID

    NCT00331526

    Start Date

    February 1 1999

    End Date

    April 1 2012

    Last Update

    March 25 2013

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Hoag Cancer Center at Hoag Memorial Hospital Presbyterian

    Newport Beach, California, United States, 92663